Quality Unlocked: Venus Remedies Renews Ukrainian GMP, Eyes Wider Markets

Image Source: Indian Pharma Post

Venus Remedies Ltd has achieved a significant milestone by renewing its Good Manufacturing Practices (GMP) certification from Ukraine’s State Service of Ukraine on Medicine and Drug Control (SMDC) for its Baddi manufacturing facility. This renewal, announced on May 22, 2025, strengthens the company’s presence in Ukraine and reinforces its global reputation for quality and compliance.

Key Highlights:

Comprehensive Certification: The renewed GMP certification covers Venus Remedies’ production lines for cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral products, including liquid and lyophilised injections, ampoules, vials, prefilled syringes, and intravenous fluids. This marks the 27th international GMP approval for the company, underlining its adherence to stringent global standards.
Strategic Market Access: The Ukrainian GMP approval is expected to facilitate further certifications from the European Medicines Agency and other Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S) member nations, opening doors to a $222 billion market across 54 countries. Venus Remedies already holds a strong presence in 16 EU countries and four PIC/S member states.
Product Portfolio and Impact: With 45 product registrations in Ukraine and 24 more in process, Venus Remedies is well-positioned to expand its offerings in one of the largest pharmaceutical markets in the CIS region. The company’s exports to Ukraine play a crucial role in supporting the country’s healthcare system, especially during challenging times.
Leadership Statement: Company executives emphasized their commitment to delivering high-quality, innovative pharmaceuticals globally and highlighted the renewed certification as a testament to their world-class manufacturing standards and ongoing expansion strategy.

This renewed GMP certification not only enhances Venus Remedies’ credibility in Ukraine but also accelerates its global growth ambitions, ensuring access to new markets and reinforcing its leadership in critical care and oncology therapeutics.

Sources: Business Upturn, Indian Pharma Post, Venus Remedies Times